….. and yet Mesoblast have had multiple meetings with the FDA about CLBP including trial parameters and even a submission for an RMAT, which was achieved earlier this year - all in 2023 while the GVHD resubmission was happening and subsequently being assessed by the FDA… go figure
I do think that any partner for CHF will want to be at the CHF FDA meeting and I have said that for a while now ….. either the way a partnership or licensing deal needs to happen in the next 2 months IMHO or we will likely see a CR way down here
GLTAH
Ann: CEO Presentation to 2023 Annual General Meeting, page-24
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |